1+ 2+ 3+ 研究表明穿刺活检和手术标本之间具有较好的一致性,以下情况下应考虑对手术标本进行重复检测: 1.细胞学/细针穿刺样本做的HER2检测 2.活检标本IHC 和 ISH 检测后HER2表达状态仍模棱两可 3.活检标本的浸润性癌太小,无法进行可靠评估 4.手术标本的形态与活检不同,如:组织学类型、组织学分级明显不同;如果淋巴结转移灶形态与原发灶明显不同,也可对转移性淋巴结进行检测 5.活检标本的HER2存在异质性(小于10% 浸润性癌HER2强而完整阳性),则应在手术标本上重复进行 HER2 检测。 以下组织学1级的癌出现HER2阳性需要考虑重做HER2 IHC:
Note
胃癌和胃食管交界腺癌 GEA, gastroesophageal adenocarcinoma;(*) Tumor cell cluster is defined as a cluster of five or more tumor cells. NOTE
附:胃癌与乳腺癌HER2对比
肠癌 HERACLES 判读标准 老标准 1+ 2+ 3+ NOTE
尿路上皮癌 HER 2 中国专家共识 A: 无着色; B:1+; C: 2+; D: 3+ NOTE
膀胱尿路上皮癌、卵巢癌等目前国际上并没有独立的判读标准指南,相关的研究对HER2 IHC的判读基本参考乳腺癌标准。 参考文献: 1.Wolff A C, Hammond M E H, Allison K H, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update[J]. Archives of pathology & laboratory medicine, 2018, 142(11): 1364-1382. 2.Rakha E A, Pinder S E, Bartlett J M S, et al. Updated UK Recommendations for HER2 assessment in breast cancer[J]. Journal of clinical pathology, 2015, 68(2): 93-99. 3.Rüschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach[J]. Modern Pathology, 2012, 25(5): 637-650. 4.Bartley A N, Washington M K, Ventura C B, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology[J]. American journal of clinical pathology, 2016, 146(6): 647-669. 5.Valtorta E, Martino C, Sartore-Bianchi A, et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study[J]. Modern Pathology, 2015, 28(11): 1481-1491. 6.中国抗癌协会肿瘤病理专业委员会, 中国临床肿瘤学会尿路上皮癌专家委员会. 中国尿路上皮癌人表皮生长因子受体2检测临床病理专家共识[J]. 中华肿瘤杂志, 2021, 43(10):6. |
|
来自: 星期天benom3m2 > 《待分类》